Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about EQRx, Inc.
EQRx, Inc. News
Oct 26, 2023 - prnewswire.com
Calling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
Oct 17, 2023 - pennystocks.com
Best Penny Stocks To Buy Now? These 3 Are Moving Fast In October
Oct 6, 2023 - businesswire.com
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
Sep 27, 2023 - businesswire.com
EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders
EQRx, Inc. Quantitative Score
About EQRx, Inc.
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
EQRx, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
EQRx, Inc. Financials
Table Compare
Compare EQRX metrics with: | |||
|---|---|---|---|
Earnings & Growth | EQRX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | EQRX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | EQRX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | EQRX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
EQRx, Inc. Income
EQRx, Inc. Balance Sheet
EQRx, Inc. Cash Flow
EQRx, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Sell |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
EQRx, Inc. Executives
| Name | Role |
|---|---|
| Ms. Dina Ciarimboli J.D. | Gen. Counsel & Corporation Sec. |
| Ms. Jamilu E. Rubin | Chief Financial Officer and Principal Financial & Accounting Officer |
| Dr. Eric E. Hedrick M.D. | Chief Physician Executive |
| Mr. Alexis A. Borisy A.M. | Founder & Executive Chairman of Board of Directors |
| Mr. Robert Forrester LL.B. | Co-Founder & Advisor |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Dina Ciarimboli J.D. | Gen. Counsel & Corporation Sec. | Female | 1969 | 628.63K |
| Ms. Jamilu E. Rubin | Chief Financial Officer and Principal Financial & Accounting Officer | Female | 1965 | 626.8K |
| Dr. Eric E. Hedrick M.D. | Chief Physician Executive | 1965 | 575.1K | |
| Mr. Alexis A. Borisy A.M. | Founder & Executive Chairman of Board of Directors | Male | 1972 | -- |
| Mr. Robert Forrester LL.B. | Co-Founder & Advisor | Male | 1964 | -- |
EQRx, Inc. Insider Trades
| Date | 9 Nov |
| Name | Casdin Eli |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 5488164 |
| Date | 9 Nov |
| Name | Casdin Eli |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 8110001 |
| Date | 9 Nov |
| Name | Casdin Eli |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 755766 |
| Date | 9 Nov |
| Name | Casdin Eli |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 101010 |
| Date | 9 Nov |
| Name | Nallicheri Melanie |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 626999 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 9 Nov | Casdin Eli | 10 percent owner | Disposed | J-Other | 5488164 |
| 9 Nov | Casdin Eli | 10 percent owner | Disposed | J-Other | 8110001 |
| 9 Nov | Casdin Eli | 10 percent owner | Disposed | J-Other | 755766 |
| 9 Nov | Casdin Eli | 10 percent owner | Disposed | J-Other | 101010 |
| 9 Nov | Nallicheri Melanie | Chief Executive Officer | Acquired | M-Exempt | 626999 |